Developing Zebrafish Models to Study the Relationship Between the Gut Microbiome and Autism Susceptibility

Citation data:

Senior Projects Spring 2015

Publication Year:
2015
Usage 432
Abstract Views 257
Downloads 175
Repository URL:
https://digitalcommons.bard.edu/senproj_s2015/123; http://digitalcommons.bard.edu/cgi/viewcontent.cgi?article=1185&context=senproj_s2015; http://digitalcommons.bard.edu/cgi/viewcontent.cgi?article=1185&context=senproj_s2015
Author(s):
Caffrey, Elisa Benedetti
Publisher(s):
Bard Digital Commons
Tags:
Autism; Zebrafish; Behavioral Testing; Microbiome; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Medical Education; Medical Immunology; Medical Microbiology; Medical Neurobiology; Neurology; Psychiatric and Mental Health
artifact description
Autism Spectrum Disorder (ASD) describes a range of neurodevelopmental disorders affecting 1 in 68 children in the United States (CDC 2014). ASD patients typically exhibit plasma hyperserotonemia and brain hyposerotonemia, indicating the serotonergic system plays a role in the autism phenotype. Serotonin is highly regulated by the gut microbiome and there is a specific signature in organism abundance in the gut microbiome of ASD patients. Zebrafish are an inexpensive vertebrate model system that develop rapidly and have a well-studied gut microbiome. To study the relationship between the gut microbiome and autism susceptibility, I derived germ-free (GF) zebrafish and created an autism-like zebrafish model using valproic acid (VPA), a common pharmaceutical used to induce autism in other model organisms. GF zebrafish displayed behavior consistent with a decrease in anxiety and a dysregulation in serotonin levels. VPA exposed zebrafish larvae displayed behavior consistent with an increase in anxiety, along with a dysregulation of serotonin levels. This study supports zebrafish as a model for ASD susceptibility, and allows for the creation of a gnotobiotic model to study the effects of species-specific abundance on the ASD phenotype and the impact of the gut microbiome on the serotonergic system, with implications for potential ASD treatment.